Cart
sales@molnova.com
Home - Products - Microbiology/Virology - HBV - Besifovir(b)

Besifovir(b)

CAS No. 441785-25-7

Besifovir(b)( —— )

Catalog No. M20442 CAS No. 441785-25-7

Besifovir a parent drug converted by LB80380 further metabolizes to its active form LB80317. LB80380 is potent antiviral agent against hepatitis B virus (HBV).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 75 In Stock
5MG 125 In Stock
10MG 195 In Stock
25MG 356 In Stock
50MG 529 In Stock
100MG 754 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Besifovir(b)
  • Note
    Research use only, not for human use.
  • Brief Description
    Besifovir a parent drug converted by LB80380 further metabolizes to its active form LB80317. LB80380 is potent antiviral agent against hepatitis B virus (HBV).
  • Description
    Besifovir a parent drug converted by LB80380 further metabolizes to its active form LB80317. LB80380 is potent antiviral agent against hepatitis B virus (HBV).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HBV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    441785-25-7
  • Formula Weight
    299.22
  • Molecular Formula
    C10H14N5O4P
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL?(835.51 mM)
  • SMILES
    Nc1ncc2ncn(CC3(CC3)OCP(O)(O)=O)c2n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Mak L Y Seto W K Lai C L et al. Pharmacokinetic evaluation of besifovir for the treatment of HBV infection[J]. Expert Opinion on Drug Metabolism & Toxicology 2018 14(1):101-106.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Burfiralimab

    Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.

  • Canocapavir

    Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.

  • IR415

    IR415 is a novel small molecule inhibitor of HBV virus replication that blocks hepatitis B virus X protein (HBx, Kd=2 nM) mediated RNAi suppression.

Sign In Join Free